Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have improved survival in many advanced cancers including advanced melanoma, renal cell, urothelial, and non-small-cell lung cancers. However, not all patients respond,...
Saved in:
| Main Authors: | Manish D. Angrish, Arun Agha, Rossanna C. Pezo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2021/9120162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of Circulating Tumor DNA in Adapting Immunotherapy Approaches in Breast Cancer
by: Sudhir Kumar, et al.
Published: (2025-06-01) -
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01) -
Gut markers for metastatic melanoma receiving immunotherapy
by: Guoping Ou, et al.
Published: (2025-07-01) -
Radiotherapy improves the clinical outcomes of recurrent or metastatic head and neck cancers treated with immunotherapy
by: Yanshuang Cheng, et al.
Published: (2025-06-01) -
Marked Erythroblast Haemophagocytosis in Association With Immunotherapy for Metastatic Melanoma
by: Tamasine Stewart, et al.
Published: (2025-06-01)